Login to Your Account

Clinic Roundup

Tuesday, September 13, 2011
Spinifex Pharmaceuticals Pty Ltd., of Victoria, Australia, presented new animal data related to its candidate EMA401 in diabetic neuropathy at the 21st annual meeting of the Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes on Sept. 11. The data showed that the drug corrected motor and sensory nerve conduction velocity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription